Generics Bulletin Explains: The Changing US Generics Market
Price Pressures Are Abating Amid Portfolio Pruning, Market Exits And Shortages
After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.
You may also be interested in...
Indian respiratory player Lupin has begun shipping its US generic version of Boehringer Ingelheim’s Spiriva HandiHaler, amid plans both to capture share from the originator’s follow-on soft mist inhalation brand and continue development of its own Respimat rival product.
Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.
Viatris has again the lauded the potential of its complex injectables and steriles pipeline, as it looks to build a business generating revenues of up to $1bn per year within the next five years.